世界の呼吸器合胞体ウイルス(RSV)治療薬市場2026:インサイト・予測

QYResearchが発行した調査報告書(QYR20NV09084)
◆英語タイトル:Global Respiratory Syncytial Virus (RSV) Therapeutics Market Insights and Forecast to 2026
◆商品コード:QYR20NV09084
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年11月(※2024年版があります。お問い合わせください。)
◆ページ数:115
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療、製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートは呼吸器合胞体ウイルス(RSV)治療薬の世界市場について調査・分析した資料です。種類別(パリビズマブ、リバビリン、その他)の市場規模、用途別(病院薬局、ドラッグストア、小売薬局、その他)の市場規模、地域別(北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等)の市場規模データ、主な企業情報と企業別市場シェア等が記載されています。
・調査範囲
・エグゼクティブサマリー
・企業別呼吸器合胞体ウイルス(RSV)治療薬の競争状況、市場シェア
・世界の呼吸器合胞体ウイルス(RSV)治療薬市場:種類別市場規模 2015年-2020年(パリビズマブ、リバビリン、その他)
・世界の呼吸器合胞体ウイルス(RSV)治療薬市場:種類別市場規模予測 2021年-2026年(パリビズマブ、リバビリン、その他)
・世界の呼吸器合胞体ウイルス(RSV)治療薬市場:用途別市場規模 2015年-2020年(病院薬局、ドラッグストア、小売薬局、その他)
・世界の呼吸器合胞体ウイルス(RSV)治療薬市場:用途別市場規模予測 2021年-2026年(病院薬局、ドラッグストア、小売薬局、その他)
・北米の呼吸器合胞体ウイルス(RSV)治療薬市場分析:米国、カナダ
・ヨーロッパの呼吸器合胞体ウイルス(RSV)治療薬市場分析:ドイツ、フランス、イギリス、イタリア、ロシア等
・アジアの呼吸器合胞体ウイルス(RSV)治療薬市場分析:日本、中国、韓国、インド、オーストラリア、台湾等
・中南米の呼吸器合胞体ウイルス(RSV)治療薬市場分析:メキシコ、ブラジル、アルゼンチン等
・中東・アフリカの呼吸器合胞体ウイルス(RSV)治療薬市場分析:トルコ、サウジアラビア、UAE等
・企業情報(企業概要、製品概要、販売量、企業動向)
- 掲載企業(変更可能性あり):Roche、AstraZeneca、Merck、AbbVie、Bausch Health、GlaxoSmithKline、ReViral、Gilead Sciences、Teva Pharmaceutical
・地域別市場規模予測(2021年-2026年):北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場
・市場機会、課題、リスク、環境分析
・バリューチェーン、販売チャネル分析
・調査の結論
【レポートの概要】

Market Analysis and Insights: Global Respiratory Syncytial Virus (RSV) Therapeutics Market
The global Respiratory Syncytial Virus (RSV) Therapeutics market size is projected to reach US$ 599.6 million by 2026, from US$ 564.7 million in 2020, at a CAGR of 5.7%% during 2021-2026.

Global Respiratory Syncytial Virus (RSV) Therapeutics Scope and Market Size
Respiratory Syncytial Virus (RSV) Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Respiratory Syncytial Virus (RSV) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Respiratory Syncytial Virus (RSV) Therapeutics market is segmented into
Palivizumab
Ribavirin
Others

Segment by Application, the Respiratory Syncytial Virus (RSV) Therapeutics market is segmented into
Hospital Pharmacies
Drug Stores
Retail Pharmacies
Others

Regional and Country-level Analysis
The Respiratory Syncytial Virus (RSV) Therapeutics market is analysed and market size information is provided by regions (countries).
The key regions covered in the Respiratory Syncytial Virus (RSV) Therapeutics market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Respiratory Syncytial Virus (RSV) Therapeutics Market Share Analysis
Respiratory Syncytial Virus (RSV) Therapeutics market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Respiratory Syncytial Virus (RSV) Therapeutics business, the date to enter into the Respiratory Syncytial Virus (RSV) Therapeutics market, Respiratory Syncytial Virus (RSV) Therapeutics product introduction, recent developments, etc.

The major vendors covered:
Roche
AstraZeneca
Merck
AbbVie
Bausch Health
GlaxoSmithKline
ReViral
Gilead Sciences
Teva Pharmaceutical

【レポートの目次】

1 Study Coverage
1.1 Respiratory Syncytial Virus (RSV) Therapeutics Product Introduction
1.2 Market Segments
1.3 Key Respiratory Syncytial Virus (RSV) Therapeutics Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size Growth Rate by Type
1.4.2 Palivizumab
1.4.3 Ribavirin
1.4.4 Others
1.5 Market by Application
1.5.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size Growth Rate by Application
1.5.2 Hospital Pharmacies
1.5.3 Drug Stores
1.5.4 Retail Pharmacies
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Estimates and Forecasts
2.1.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue 2015-2026
2.1.2 Global Respiratory Syncytial Virus (RSV) Therapeutics Sales 2015-2026
2.2 Global Respiratory Syncytial Virus (RSV) Therapeutics, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Respiratory Syncytial Virus (RSV) Therapeutics Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Respiratory Syncytial Virus (RSV) Therapeutics Competitor Landscape by Players
3.1 Respiratory Syncytial Virus (RSV) Therapeutics Sales by Manufacturers
3.1.1 Respiratory Syncytial Virus (RSV) Therapeutics Sales by Manufacturers (2015-2020)
3.1.2 Respiratory Syncytial Virus (RSV) Therapeutics Sales Market Share by Manufacturers (2015-2020)
3.2 Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Manufacturers
3.2.1 Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Manufacturers (2015-2020)
3.2.2 Respiratory Syncytial Virus (RSV) Therapeutics Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Respiratory Syncytial Virus (RSV) Therapeutics Revenue in 2019
3.2.5 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Respiratory Syncytial Virus (RSV) Therapeutics Price by Manufacturers
3.4 Respiratory Syncytial Virus (RSV) Therapeutics Manufacturing Base Distribution, Product Types
3.4.1 Respiratory Syncytial Virus (RSV) Therapeutics Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Respiratory Syncytial Virus (RSV) Therapeutics Product Type
3.4.3 Date of International Manufacturers Enter into Respiratory Syncytial Virus (RSV) Therapeutics Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size by Type (2015-2020)
4.1.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Sales by Type (2015-2020)
4.1.2 Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Type (2015-2020)
4.1.3 Respiratory Syncytial Virus (RSV) Therapeutics Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast by Type (2021-2026)
4.2.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast by Type (2021-2026)
4.2.2 Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast by Type (2021-2026)
4.2.3 Respiratory Syncytial Virus (RSV) Therapeutics Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Market Size by Application (2015-2026)
5.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size by Application (2015-2020)
5.1.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Sales by Application (2015-2020)
5.1.2 Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Application (2015-2020)
5.1.3 Respiratory Syncytial Virus (RSV) Therapeutics Price by Application (2015-2020)
5.2 Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast by Application (2021-2026)
5.2.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast by Application (2021-2026)
5.2.2 Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast by Application (2021-2026)
5.2.3 Global Respiratory Syncytial Virus (RSV) Therapeutics Price Forecast by Application (2021-2026)

6 North America
6.1 North America Respiratory Syncytial Virus (RSV) Therapeutics by Country
6.1.1 North America Respiratory Syncytial Virus (RSV) Therapeutics Sales by Country
6.1.2 North America Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Type
6.3 North America Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Application

7 Europe
7.1 Europe Respiratory Syncytial Virus (RSV) Therapeutics by Country
7.1.1 Europe Respiratory Syncytial Virus (RSV) Therapeutics Sales by Country
7.1.2 Europe Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Type
7.3 Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Application

8 Asia Pacific
8.1 Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics by Region
8.1.1 Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Sales by Region
8.1.2 Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Type
8.3 Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Application

9 Latin America
9.1 Latin America Respiratory Syncytial Virus (RSV) Therapeutics by Country
9.1.1 Latin America Respiratory Syncytial Virus (RSV) Therapeutics Sales by Country
9.1.2 Latin America Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Type
9.3 Central & South America Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Application

10 Middle East and Africa
10.1 Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics by Country
10.1.1 Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Sales by Country
10.1.2 Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Type
10.3 Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Facts & Figures by Application

11 Company Profiles
11.1 Roche
11.1.1 Roche Corporation Information
11.1.2 Roche Description and Business Overview
11.1.3 Roche Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Roche Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.1.5 Roche Related Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Corporation Information
11.2.2 AstraZeneca Description and Business Overview
11.2.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.2.4 AstraZeneca Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.2.5 AstraZeneca Related Developments
11.3 Merck
11.3.1 Merck Corporation Information
11.3.2 Merck Description and Business Overview
11.3.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Merck Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.3.5 Merck Related Developments
11.4 AbbVie
11.4.1 AbbVie Corporation Information
11.4.2 AbbVie Description and Business Overview
11.4.3 AbbVie Sales, Revenue and Gross Margin (2015-2020)
11.4.4 AbbVie Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.4.5 AbbVie Related Developments
11.5 Bausch Health
11.5.1 Bausch Health Corporation Information
11.5.2 Bausch Health Description and Business Overview
11.5.3 Bausch Health Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Bausch Health Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.5.5 Bausch Health Related Developments
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Corporation Information
11.6.2 GlaxoSmithKline Description and Business Overview
11.6.3 GlaxoSmithKline Sales, Revenue and Gross Margin (2015-2020)
11.6.4 GlaxoSmithKline Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.6.5 GlaxoSmithKline Related Developments
11.7 ReViral
11.7.1 ReViral Corporation Information
11.7.2 ReViral Description and Business Overview
11.7.3 ReViral Sales, Revenue and Gross Margin (2015-2020)
11.7.4 ReViral Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.7.5 ReViral Related Developments
11.8 Gilead Sciences
11.8.1 Gilead Sciences Corporation Information
11.8.2 Gilead Sciences Description and Business Overview
11.8.3 Gilead Sciences Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Gilead Sciences Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.8.5 Gilead Sciences Related Developments
11.9 Teva Pharmaceutical
11.9.1 Teva Pharmaceutical Corporation Information
11.9.2 Teva Pharmaceutical Description and Business Overview
11.9.3 Teva Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Teva Pharmaceutical Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.9.5 Teva Pharmaceutical Related Developments
11.1 Roche
11.1.1 Roche Corporation Information
11.1.2 Roche Description and Business Overview
11.1.3 Roche Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Roche Respiratory Syncytial Virus (RSV) Therapeutics Products Offered
11.1.5 Roche Related Developments

12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Respiratory Syncytial Virus (RSV) Therapeutics Market Estimates and Projections by Region
12.1.1 Global Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast by Regions 2021-2026
12.1.2 Global Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast by Regions 2021-2026
12.2 North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast (2021-2026)
12.2.1 North America: Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast (2021-2026)
12.2.2 North America: Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast (2021-2026)
12.2.3 North America: Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast by Country (2021-2026)
12.3 Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast (2021-2026)
12.3.1 Europe: Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast (2021-2026)
12.3.2 Europe: Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast (2021-2026)
12.3.3 Europe: Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast by Region (2021-2026)
12.5 Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast (2021-2026)
12.5.1 Latin America: Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast (2021-2026)
12.5.2 Latin America: Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast (2021-2026)
12.5.3 Latin America: Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Respiratory Syncytial Virus (RSV) Therapeutics Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Respiratory Syncytial Virus (RSV) Therapeutics Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Respiratory Syncytial Virus (RSV) Therapeutics Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Respiratory Syncytial Virus (RSV) Therapeutics Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Respiratory Syncytial Virus (RSV) Therapeutics Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer

...

【掲載企業】

Roche、AstraZeneca、Merck、AbbVie、Bausch Health、GlaxoSmithKline、ReViral、Gilead Sciences、Teva Pharmaceutical

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の呼吸器合胞体ウイルス(RSV)治療薬市場2026:インサイト・予測(Global Respiratory Syncytial Virus (RSV) Therapeutics Market Insights and Forecast to 2026)]についてメールでお問い合わせはこちらでお願いします。